ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
Curt	Kurt	3:18		Vanderbilt opening
5,895,000	5,859,006	5:7		Vanderbilt opening
vaned built	Vanderbilt	5:25		Vanderbilt opening
place apart	plays a part	6:9		Vanderbilt opening
vess. Els	vessels	6:13		Vanderbilt opening
relax Asian	relaxation	6:14		Vanderbilt opening
phenyltio	phenylthio	14:8		Vanderbilt opening
phenyltio	phenylthio	14:14		Vanderbilt opening
84	8,4	14:22		Vanderbilt opening
phenyltio	phenylthio	14:23		Vanderbilt opening
phenyltio	phenylthio	17:16		Vanderbilt opening
phenyltio	phenylthio	18:1		Vanderbilt opening
phenyltio	phenylthio	20:1		Vanderbilt opening
8 substitute of	8 substituted	20:20		Vanderbilt opening
phenyltio	phenylthio	21:2		Vanderbilt opening
PD	PDE	21:8		Vanderbilt opening
PD-five	PDE 5	23:2		Vanderbilt opening
DCCE	BCCE	23:3		Vanderbilt opening
guanomolar	nanomolar	23:6		Vanderbilt opening
tail	tale	23:18		Vanderbilt opening
DZD	BZD	24:5		Vanderbilt opening
BZEs	BZDs	24:6		Vanderbilt opening
VZD	BZD	25:23		Vanderbilt opening
10040	140	26:16		Vanderbilt opening
Isys	ISIS	26:17		Vanderbilt opening
nine tease	90's	26:21		Vanderbilt opening
Isys	ISIS	26:24		Vanderbilt opening
enjoin	join	27:24		Vanderbilt opening
phenyltio	phenylthio	28:3		Vanderbilt opening
Isys	ISIS	28:12		Vanderbilt opening
whack key	whacky	28:15		Vanderbilt opening
cam bell	Campbell	30:1		Vanderbilt opening
bath	Bath	30:1		Vanderbilt opening
confirmation naturally	conformationally	30:15		Vanderbilt opening
strain	straighten	30:20		Vanderbilt opening
PDF	PDE	30:23		Vanderbilt opening
confirmation naturally	conformationally	30:25		Vanderbilt opening

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 1 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
hot	lot	34:14		Vanderbilt opening
Rich Eserve	Richie Serp	37:10		ICOS opening
Eli Lily	Eli Lilly	37:12		ICOS opening
Cornelio	Corneglio	37:13		ICOS opening
chemist tree experts	chemistry experts	37:16		ICOS opening
Dr. Albert Paubra from Emery University,	Dr. Albert Padwa from Emory University,	37:17		ICOS opening
method as claimed	method claimed	38:2		ICOS opening
if	[delete if]	38:13		ICOS opening
cop firm	confirm	38:18		ICOS opening
in	on	39:6		ICOS opening
is was actually	is what is actually	39:9-10		ICOS opening
American Biosciences.	American Bioscience.	39:18		ICOS opening
American bio science	American Bioscience	40:5		ICOS opening
those	to those	40:9		ICOS opening
with	to	40:21		ICOS opening
patent issue,	patent-at-issue,	40:24		ICOS opening
must may have	must have	41:2		ICOS opening
here	hear	43:24		ICOS opening
and Francis chemically only Dr. Daugan	and frankly only Dr. Daugan	44:7-8		ICOS opening
heat cycles	heterocycles	44:13		ICOS opening
some of the compounds that. Dr. Daugan designed and synthesized	some of the compounds that Dr. Daugan designed and synthesized	46:12-13		ICOS opening
selected	selective	46:24		ICOS opening
once	ones	47:6		ICOS opening
IBM	IBMX	47:9		ICOS opening
they're	there's	48:16		ICOS opening
phenyltio-IBMX	phenylthio-IBMX	48:19		ICOS opening
hydrophobe I object group	hydrophobic group	48:23		ICOS opening
medicinal chemistry	medicinal chemist	49:12		ICOS opening
grants	France	49:19		ICOS opening
under the law to have him find for co-inventors	under the law to find co-inventorship	50:14-15		ICOS opening
place of	facts	50:17		ICOS opening
new	knew	51:5		ICOS opening
medicinal chemist tree	medicinal chemistry	51:12		ICOS opening

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 2 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
pulse	pulls	51:16		ICOS opening
which	while	53:1		ICOS opening
pulse	pulled	53:16		ICOS opening
thing.	things.	54:6		ICOS opening
concede	conceive	54:10		ICOS opening
conceded	conceived	54:12		ICOS opening
Dr. Brennen	Mr. Brennen	55:16		ICOS opening
beta-carbolines and zabrinast	IBMX and zaprinast	58:15-16		ICOS opening
with zabrinast analogs and piperazine quinoxilline series and	with zaprinast analogs and piperzine imidazequinexilinane series and	58:25		ICOS opening
Labaudiniere	Daugan	59:5		ICOS opening
piperinedione	piperizinedione	59:21		ICOS opening
300040X	30040X	60:1		ICOS opening
used	use	60:25		ICOS opening
It also describes that it can be used for altering.	it also describes that it can be used for altering the cGMP levels.	62:23		ICOS opening
alleges scientists	alleges its scientists	63:8		ICOS opening
Formula 11	Formula I	63:19		ICOS opening
1	12	64:22		ICOS opening
methylinedioxy	methylenedioxy	65:10-11		ICOS opening
329 patent sufficiently	'329 patent-at-issue	66:9		ICOS opening
329 patent sufficiently	'329 patent-at-issue	66:20		ICOS opening
in fact arrest as I said of about,	in fact just as I said,	67:6-7		ICOS opening
joint inconvenient torques	joint co-inventors	67:21		ICOS opening
Vanderbilt sign tints	Vanderbilt scientists	68:15		ICOS opening
should you back.	Chugai.	68:20		ICOS opening
American bio science	American Bioscience	69:23-24		ICOS opening
compunds in this case, while the co-scientist was pursuing informed modifications to beta-carboline-type compounds,	compunds in this case, while the inventor was pursuing different modifications to beta-carboline-type compounds,	70:7-8		ICOS opening
to	on	70:12		ICOS opening
that they suggest that the incorporation of side groups,	that they suggested the incorporation of side groups,	70:18		ICOS opening
pro proposing	proposing	71:10-11		ICOS opening
I may continue.	You may continue.	73:5		ICOS opening

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 3 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
him.	himself.	73:21		ICOS opening
it's in dispute	it's not in dispute	73:22		ICOS opening
September err	center	74:3-4		ICOS opening
arrests	as	74:20		ICOS opening
compound	compounds	75:9		ICOS opening
Glax	Glaxo	75:22		ICOS opening
January 19, '92.	January 1992.	76:2		ICOS opening
likes	like	76:18		ICOS opening
an	and	77:1		ICOS opening
He was the manager in charge of the whole sheeting match basically,	He was the manager in charge of the whole shooting match basically,	77:16-17		ICOS opening
various series. that were	various series that were	77:19-20		ICOS opening
B100	APO B100	78:15		ICOS opening
there by	thereby	79:8		ICOS opening
CI23002	CCI23002	79:13		ICOS opening
So in this may time period, after it had been identifed that their GR5273	So in this May time period, after it had been identified that their GR35273	79:16-17		ICOS opening
had been identified had been identified	had been identified	79:19-20		ICOS opening
as say	assay	80:20		ICOS opening
source	stocks	81:11		ICOS opening
four structure	sub-structure	81:13		ICOS opening
lying	like	81:14		ICOS opening
quito	keto	83:10		ICOS opening
intuited	determined	84:14		ICOS opening
quito	keto	88:10		ICOS opening
thionene	thienyl	89:15		ICOS opening
when	whether	90:23		ICOS opening
was	were	92:17		ICOS opening
solely	sole	93:11		ICOS opening
Dr. Cody	Dr. Cote	96:21		ICOS opening
work of haw many groups.	work of many groups.	97:6		ICOS opening
Apotech	Apotex	97:8		ICOS opening

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 4 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
would fail to realize that a PDE inhibitor such acid cooperated to inhibit cGMP PED in the smooth muscle in	would fail to realize that a PDE inhibitor such as Viagra could inhibit cGMP PDE in the smooth muscle in	97:10-11		ICOS opening
Dr. Corwin	Dr. Corbin	97:20		ICOS opening
recollections.	erections.	98:23		ICOS opening
of the molecular functions of a body	of molecular functions in the body	102:10-11	Corbin	Direct
guanile	guanylyl	102:17	Corbin	Direct
guanile	guanylyl	102:20	Corbin	Direct
guanile	guanylyl	102:21	Corbin	Direct
enclose	close	104:22	Corbin	Direct
change go	changing	107:8	Corbin	Direct
this guanlyl cyclase lumen	this lumen	107:22	Corbin	Direct
known as, which	known as, cyclic GMP-dependent protein kinase	108:7	Corbin	Direct
signalling. Here comes her come from a cycle from outside.	signaling from outside causing cyclic GMP to go up.	108:9	Corbin	Direct
depicting smooth	depicting a smooth	111:8	Corbin	Direct
is covered	was discovered	114:1	Corbin	Direct
AMP in PKA	AMP and PKA	114:2	Corbin	Direct
Forget	function	114:6	Corbin	Direct
tomorrow	Tom	114:10	Corbin	Direct
GMP From	GMP binding protein from	115:1	Corbin	Direct
it pound bound	it bound	115:25	Corbin	Direct
informs foe December trace	the same protein	116:23	Corbin	Direct
modulated	calmodulin	117:2	Corbin	Direct
cyclic stimulated	cyclic GMP stimulated	117:4	Corbin	Direct
PD2	PDE2	117:5	Corbin	Direct
electro pharmacology	Molecular Pharmacology	117:12-13	Corbin	Direct
messenger of cyclic, what	messenger cyclic GMP what	118:3	Corbin	Direct
microstructure	molecularstructure	119:15	Corbin	Direct
together, with the	together, the	119:16	Corbin	Direct
forced	fused	119:18	Corbin	Direct
molecule	model	120:4	Corbin	Direct
phenyl thiocyclic GMP	phenylthio cyclic GMP	122:4	Corbin	Direct
phenyl thiocyclic GMP	phenylthio cyclic GMP	123:7	Corbin	Direct
cyclic PKA	cyclic GMP	123:23	Corbin	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 5 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
Big	pig	123:25	Corbin	Direct
state	study	124:2	Corbin	Direct
who is of the cardiovascular	who was head of the cardiovascular	125:15	Corbin	Direct
analog.	analogs.	128:22	Corbin	Direct
there are all right but the	there the	130:15	Corbin	Direct
says they are	says are	130:16	Corbin	Direct
those surrounding out.	those.	130:17	Corbin	Direct
there is something	there are some amino acids that are	130:17	Corbin	Direct
indicating	indicated	130:18	Corbin	Direct
R	Arg	130:19	Corbin	Direct
symptomatic	systematic	132:5	Corbin	Direct
arginine, leucinine	arginine, Leu is leucine	130:20	Corbin	Direct
certain proteins	certain amino acids	130:22	Corbin	Direct
right on	around	131:3	Corbin	Direct
we could see	you can see	131:6	Corbin	Direct
thi	phe	131:10	Corbin	Direct
acid, 15 alanine	acid phenylananine	131:13	Corbin	Direct
to it.	to them.	131:15	Corbin	Direct
normally	such a group	131:15	Corbin	Direct
thi	phe	131:16	Corbin	Direct
take placement	make contact	131:23	Corbin	Direct
was post-doctoral	was a post-doctoral	132:21	Corbin	Direct
Webber	Weber	132:23	Corbin	Direct
8	a	133:13	Corbin	Direct
numbers - now	numbers K prime a	133:22	Corbin	Direct
eight	a	133:25	Corbin	Direct
analogue	analogues	134:4	Corbin	Direct
once	ones	134:7	Corbin	Direct
Latent	Leighton	134:24	Corbin	Direct
with	at	135:10	Corbin	Direct
doctor recommend I'll lease lab?	Glaxo in November?	138:18-19	Corbin	Direct
Layton	Leighton	138:20	Corbin	Direct
Domenico	Domanico	138:21	Corbin	Direct
Beevo	Beavo	139:15	Corbin	Direct
scientist	scientists	139:17	Corbin	Direct
Layton…. Domenico…Beevo	Leighton ….Domanico…Beavo	139:18	Corbin	Direct
from --- we	from sea urchin sperm. We	140:5	Corbin	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 6 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
of clone	of a clone	140:6	Corbin	Direct
Beevo	Beavo	140:20	Corbin	Direct
possible exhibits	possibility	140:23	Corbin	Direct
binding, PDE-5, and first	binding PDE-5, and the first	141:13	Corbin	Direct
PD-5	PDE 5	141:25	Corbin	Direct
in	and	142:9	Corbin	Direct
PD-5	PDE-5	142:13	Corbin	Direct
GPE	GMP	143:5	Corbin	Direct
journal	Journal	143:10	Corbin	Direct
of Chemistry	of Biological Chemistry	143:11	Corbin	Direct
directed phosphodiesterase	directed regulation of phosphodiesterase	143:12	Corbin	Direct
PD-5	PDE-5	143:13	Corbin	Direct
of enzyme	of the enzyme	143:19	Corbin	Direct
works	words	143:23	Corbin	Direct
photo diesterase	phosphodiesterase	143:24	Corbin	Direct
had who	whom	146:1	Corbin	Direct
big	pig	146:9	Corbin	Direct
proteinkinase...phosphodiase	protein kinase...phophodiesterase	146:16	Corbin	Direct
Perdi	Kirksey	147:1	Corbin	Direct
sent	send	147:5	Corbin	Direct
cyclogenic	cyclic GMP	147:23	Corbin	Direct
EKG	PKG	147:24	Corbin	Direct
facive	FASEB	149:4	Corbin	Direct
society	societies	149:5	Corbin	Direct
Fogenti's	Konjeti's	149:8	Corbin	Direct
amino	meet other	149:12	Corbin	Direct
derivative advertised	derivatised	149:17	Corbin	Direct
CK-1	PKG	149:19	Corbin	Direct
than CGK - 1 beta.	PKG-1 alpha over PKG-1 beta.	149:21	Corbin	Direct
O-H,	OH,	149:22	Corbin	Direct
N-H2, and O-C-H3	NH2, and OCH3	149:23	Corbin	Direct
CK-1	PKG-I	149:24	Corbin	Direct
In FASEB	In a FASEB	150:1	Corbin	Direct
thi	phe	150:7	Corbin	Direct
for GLAXO	For the GLAXO	151:8	Corbin	Direct
Pittsburgh	Pittsboro	151:9	Corbin	Direct
blow	below	151:20	Corbin	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 7 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
psychogenic	cGMP	151:22	Corbin	Direct
extra.....psychogenic	vascular....cGMP	151:24	Corbin	Direct
Remele	Rimele	152:17	Corbin	Direct
find	bind	153:18	Corbin	Direct
84 chlorophenylthiro	8, 4 chlorophenylthio	154:24	Corbin	Direct
a parachlorophenyl -it's the same as 4-chlorophenyl GMP compound.	8-parachlorophenylthio-cyclic GMP it's the same as 8-4-chlorphenylthio-cyclic compound.	155:8	Corbin	Direct
Brenner	Brennen	157:23	Corbin	Direct
analog we	analogs that we	162:9	Corbin	Direct
GNP were analogs	GMP analogs	162:25	Corbin	Direct
GNP	GMP	163:1	Corbin	Direct
Kinjay	Konjeti	163:2	Corbin	Direct
8 cGMP,	8-cGMP analogs,	163:13	Corbin	Direct
withdrawing donating	withdrawing/donating	163:18	Corbin	Direct
confirmation	confirmation	163:17	Corbin	Direct
confirmation	conformation	163:21	Corbin	Direct
B9	9	164:3	Corbin	Direct
confirmation, is the syn confirmation	the syn conformation	164:7	Corbin	Direct
confirmation	conformation	164:10	Corbin	Direct
confirmation	conformation	164:12	Corbin	Direct
cGMP logs	cGMP analogs	164:16	Corbin	Direct
such analog	such an analog	164:20	Corbin	Direct
confirmation....any conformation	Confirmation.....into the anti conformation	164:24	Corbin	Direct
Keeney, Don Kirsksy	Keeney, and Don Kirskey	166:21	Corbin	Direct
from	of	166:22	Corbin	Direct
Kirksy	Kirksey	167:12	Corbin	Direct
in	unit to	167:14	Corbin	Direct
interest	interests	167:16	Corbin	Direct
me go	[delete me go]	170:12	Corbin	Direct
question,	question of	172:11	Corbin	Direct
more.	more to PDE5	172:15	Corbin	Direct
PD-5 .....--but first grant	PDE 5.....grant	172:16	Corbin	Direct
mainly.	mainly PKG.	172:17	Corbin	Direct
go toward PD-5	go more toward PDE 5	172:18	Corbin	Direct
suggested people	suggested Glaxo people	172:19	Corbin	Direct
outside - we	outside Vanderbilt. We	173:20	Corbin	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 8 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
would synthesize	had synthesized	173:22	Corbin	Direct
talking, which ones?	talking about which ones?	174:23	Corbin	Direct
the - down	the space down	174:25	Corbin	Direct
Vivo's	Beavo's	175:25	Corbin	Direct
Dr. Vivo's	Dr. Beavo's	176:2	Corbin	Direct
but we got	and we did	176:7	Corbin	Direct
with Glaxo responding sponsoring compounds	with a Glaxo response in sponsoring our compounds	176:22	Corbin	Direct
to - we built better if it was sponsored.	if Vanderbilt would sponsor our compounds.	176:25	Corbin	Direct
It ....GMP	There...PKG	178:20	Corbin	Direct
in attached	intact	180:4	Corbin	Direct
call	called	180:8	Corbin	Direct
phosphodiester	phosphodiesterase	181:3	Corbin	Direct
3-iosbutylmethyl xanthene or IBMX	3-isobutylmethylxanthine or IBMX,	181:5	Corbin	Direct
Phosphodiase	phosphodiesterase	181:10	Corbin	Direct
has	sits	182:1	Corbin	Direct
enclosed with	enclosed, with	182:2	Corbin	Direct
acid	acids	182:3	Corbin	Direct
they	there	182:7	Corbin	Direct
a	the	185:2	Corbin	Direct
PD-5	PDE 5	185:5	Corbin	Direct
one analogue	one IBMX analogue	185:8	Corbin	Direct
Modified	also	185:9	Corbin	Direct
is	was	186:4	Corbin	Direct
and their	in their	187:21	Corbin	Direct
doctor hash	Dr. Hash	188:19-20	Corbin	Direct
hear	here	188:21	Corbin	Direct
Cyclic Binding CMPE	Cyclic Binding PDE	189:22	Corbin	Direct
84hydroxy phenyltio-IBMX, showing	8-4- hydroxyphenylthio-IBMX, shows	189:24	Corbin	Direct
164 more	160 times more	189:25	Corbin	Direct
you we had.....letter, didn't	about...letter, but didn't	190:4	Corbin	Direct
either	it is	190:5	Corbin	Direct
at A	In A,	190:9	Corbin	Direct
a synsthesizing test	to be synthesized.	190:10	Corbin	Direct
8-4 hydroxy phenyl thigh O IBM M IBMX	8-4-hydroxyphenylthio IBMX	190:16-17	Corbin	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 9 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 7, 2008 (D.I. 140)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination type
Kijenti	Konjeti	190:23	Corbin	Direct
zapernast	zaprinast	191:16	Corbin	Direct
8, higher hydroxy phenyl thigh O IBMX	analog 8-4- hydroxyphenylthio-IBMX	192:12-13	Corbin	Direct
little ago	little while ago	193:24	Corbin	Direct
he was	we were	194:14	Corbin	Direct
that's will already	[delete will]	194:15	Corbin	Direct
is we	our	194:21	Corbin	Direct
In	on	194:23	Corbin	Direct
is	was	195:15	Corbin	Direct
Elve ... fare	Elves....affairs	197:12	Corbin	Direct
And I	And asked if I	200:11	Corbin	Direct
Kijenti	Konjeti	201:15	Corbin	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 10 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
analogue	analogues	208:10	Corbin	Direct
bath's ….bath's	baths……baths	209:7	Corbin	Direct
Affix	effects	209:8	Corbin	Direct
analogue	analogues	209:9	Corbin	Direct
test.	tests.	209:14	Corbin	Direct
paper 1980 and	paper of 1980 in the	210:21	Corbin	Direct
Labs	lab	211:5	Corbin	Direct
Cite	Site	212:24	Corbin	Direct
cyclicing	cyclic	212:25	Corbin	Direct
Glaxo	Molecular	213:4	Corbin	Direct
formulation	phosphorylation	213:10	Corbin	Direct
Back	book	213:20	Corbin	Direct
Regulation Drug	Regulation and Drug	214:2	Corbin	Direct
1985, and	1985, in	215:1	Corbin	Direct
current topics, sale regulation.	Current Topics in Cell Regulation	215:2	Corbin	Direct
Cloned	clone	216:19	Corbin	Direct
Pharmacology	Pharmacologist	220:1	Corbin	Direct
IC 50s	IC-50s	220:17	Corbin	Direct
248 is Joint Exhibit 47	241 is Joint Exhibit 47	222:17	Corbin	Direct
IBM	GMP	222:25	Corbin	Direct
testing various	testing on various	223:1	Corbin	Direct
I got	I get	223:13	Corbin	Direct
he…get the drugs….spent	they….be used as…sent	224:2	Corbin	Direct
Exhibit No. 256	Exhibit No. 265	225:13	Corbin	Direct
Nuigi	Guigi	225:23	Corbin	Direct
Joint Exhibit 60 six	Joint Exhibit 66	227:4	Corbin	Direct
exhibit 362	exhibit 305	229:2	Corbin	Direct
Yatson	Jahnsen	232:6	Corbin	Direct
phosphodiesterase inhibitors	Phosphodiesterase Inhibitors	235:16	Corbin	Direct
design and synthesis of xanthines and cyclic	Design and Synthesis of Xanthines and Cyclic	235:17	Corbin	Direct
analogs as potent inhibitors	Analogs as Potent Inhibitors	235:18	Corbin	Direct
an acting	the active	237:6	Corbin	Direct
Glaxo's	ICOS's	237:14	Corbin	Direct
Glaxo	ICOS	237:15	Corbin	Direct
Viagara	Viagra	238:3	Corbin	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 11 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
so....were	but ...were	238:4	Corbin	Direct
actually	difficulty	241:3	Corbin	Direct
he	we	245:19	Corbin	Cross
been performed,	been performed,"	247:9	Corbin	Cross
efficacy	efficacious	247:20	Corbin	Cross
psychogenic	cyclic GMP	248:1	Corbin	Cross
lacked	looked like	249:23	Corbin	Cross
one really	study	250:4	Corbin	Cross
once.	ones.	250:21	Corbin	Cross
were	will	250:24	Corbin	Cross
You were agree ...pursuing - -	You will agree...pursuing PDE-5 inhibitors?	250:24-25	Corbin	Cross
this the	this is the	251:13	Corbin	Cross
would select for PDEs	would be selective for PDEs	252:14	Corbin	Cross
I	it	253:5	Corbin	Cross
It was did,	[delete did]	253:7	Corbin	Cross
CGMP analogs; correct?	Q. cGMP analogs; correct?	254:7	Corbin	Cross
cyclic PDE	cyclic GMP	254:10	Corbin	Cross
pack	back	254:15	Corbin	Cross
sel ectivity	selectivity	254:16	Corbin	Cross
analogue	analogues	254:17	Corbin	Cross
ori ginal	original	254:19	Corbin	Cross
inhibitors ever of	inhibitors of	255:6	Corbin	Cross
IBM	IBMX	255:8	Corbin	Cross
selected	selective	255:12	Corbin	Cross
I C fifties	IC50s	255:24	Corbin	Cross
84 hydroxy phenylthio IBMX	8-4- hydroxyphenylthio-IBMX	256:4	Corbin	Cross
carrot	caret	256:14	Corbin	Cross
selected	selective	257:5	Corbin	Cross
You would agree with me generally, though, that the	Q. You would agree with me generally, though, that the	257:8	Corbin	Cross
selected	selective	257:16	Corbin	Cross
sides	sites	258:14	Corbin	Cross
selected	selective	258:15	Corbin	Cross
an hogs	analogs	259:9	Corbin	Cross
8 bromo PET cyclic GMP	8 -bromo- PET- cyclic GMP	260:3	Corbin	Cross
not pharmacologist	not the pharmacologist	260:22	Corbin	Cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 12 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
24 dihydroxy	2,4-dihydroxy	261:4	Corbin	Cross
finger....8 bromo pet 1	Figure.....8- bromo-PET-cyclic GMP.	261:9	Corbin	Cross
benzo	benzyl	261:13	Corbin	Cross
wherever	were ever	261:14	Corbin	Cross
compound	compounds	264:11	Corbin	Cross
claim	claimed	269:6	Corbin	Cross
patents in at issue	[delete in]	272:10	Corbin	Cross
MR. BRENNEN:	MR. FLOWERS:	274:21	Corbin	Cross
compound	compounds	275:19	Corbin	Cross
selected	selective	281:11	Corbin	Cross
the first group to publicly disclose the of treating PDE-5 inhibition	the first group to publicly disclose the role of PDE-5 inhibition in treating impotence	282:8-9	Corbin	Cross
hem?	him?	284:4	Corbin	Cross
identify	identified	284:7	Corbin	Cross
identify	identified	284:19	Corbin	Cross
the 84 hydroxy phenyl-thio IBMX	the 8-4 hydroxy phenyl-thio IBMX	285:14	Corbin	Cross
analogue	analogues	286:17	Corbin	Cross
eight - the	eight to resemble	286:21	Corbin	Cross
PET. Cyclic	PET-Cyclic	289:5	Corbin	Cross
PET	PET-cyclic GMP	289:7	Corbin	Cross
direct	directed	289:14	Corbin	Cross
hydrophobe	[delete hydrophobe]	289:17	Corbin	Cross
eight hydroxy phenyl thigh yo IBMX.	8-4 hydroxy phenyl-thio IBMX.	289:19	Corbin	Cross
said.	sent.	289:20	Corbin	Cross
24 hydroxy phenyl thigh yo PET.	2-4 hydroxy phenyl-thio PET.	289:22	Corbin	Cross
PET cyclic ...12	PET-cyclic....1,2	289:24	Corbin	Cross
cyclic - it's	Cyclic GMP it's	289:25	Corbin	Cross
analogue	analogues	293:10	Corbin	Cross
it.	it."	293:23	Corbin	Cross
c-GMP.	cGMP."	294:3	Corbin	Cross
went	wanted	295:22	Corbin	Cross
unit	in it	296:12	Corbin	Cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 13 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
Our cyclic GMP analogues or PG, BPDE,	Our cyclic GMP analogues and cGMP-BPDE,	298:17	Corbin	Cross
now the context	knew existed	300:8	Corbin	Cross
Cialis	Viagra	302:20	Corbin	Cross
lab	labs	304:24	Corbin	Cross
soon teen	xanthine	305:19	Corbin	Cross
difference	differences	305:20	Corbin	Cross
undergo	analog	306:7	Corbin	Cross
84 hydroxy phenylthio IBMX	8-4-hydroxyphenylthio-IBMX	308:11	Corbin	Cross
And all	Analog	308:21	Corbin	Cross
marked with bucket	appended with hydrophobic	309:3	Corbin	Cross
feed	Hydrophobic	310:23	Corbin	Cross
fee	phe	311:11	Corbin	Cross
fee	Phe	311:16	Corbin	Cross
Molecule	Molecular	312:21	Corbin	Cross
fee	phe	313:24	Corbin	Cross
CDMA	cDNA	315:22	Corbin	Cross
DDE-5	PDE-5	318:9	Corbin	Cross
selected	selective	320:10	Corbin	Cross
selected	selective	320:11	Corbin	Cross
selected	selective	320:25	Corbin	Cross
set	said	321:10	Corbin	Cross
So a four micromolar IC50 was exciting data,	"So a four micromolar IC50 was exciting data,"	321:7-8	Corbin	Cross
And you set, it was, ... it look like;	And you said, "it was, ... it looks like";	321:10-12	Corbin	Cross
these owe of	[delete these owe of]	321:11	Corbin	Cross
look	looks	321:11	Corbin	Cross
Dr. Daugan's	Dr. Grondin's	323:17	Corbin	Cross
Dr. Daugan	Dr. Grondin	323:20	Corbin	Cross
was	with	328:23	Corbin	Cross
sent	send	328:25	Corbin	Cross
amine	amino	330:8	Corbin	Cross
amine	amino	330:10	Corbin	Cross
amine	amino	330:16	Corbin	Cross
amine	amino	330:22	Corbin	Cross
bindings	Binding	331:6	Corbin	Cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 14 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
PKG, No. 1	PKG-1	332:5	Corbin	Cross
Acids	Acid	332:7	Corbin	Cross
difference	different	332:8	Corbin	Cross
it's	[delete it's]	332:11	Corbin	Cross
sin	syn	333:19	Corbin	Cross
kinase	PDE5	333:24	Corbin	Cross
went	wanted	334:7	Corbin	Cross
Cialis	Viagra	336:18	Corbin	Redirect
Cialis	Viagra	336:20	Corbin	Redirect
maim	male	338:25	Corbin	Redirect
identify	identified	340:3	Corbin	Redirect
I	He	341:4	Corbin	Redirect
illucidation	elucidation	344:6	Crooks	Direct
discipline	disciplines	344:8	Crooks	Direct
alkaloid	Alkaloids	344:11	Crooks	Direct
sciences, very	sciences, it is very	344:23	Crooks	Direct
pharmacology, clinical	Pharmacology, and clinical	345:2	Crooks	Direct
baccalaureate. Then	baccalaureate, then	345:11	Crooks	Direct
at	on	345:21	Crooks	Direct
lecture remember an	lecture; I remember I	345:23	Crooks	Direct
remember	[delete remember]	345:24	Crooks	Direct
to the	to	346:13	Crooks	Direct
Cowell	Coward	346:15	Crooks	Direct
Wellington	Wethington	346:17	Crooks	Direct
for	from	346:19	Crooks	Direct
Bridge	the British	346:20	Crooks	Direct
also - several	also hold several	346:22	Crooks	Direct
scientists	societies	346:23	Crooks	Direct
meritorious a work	meritorious work	347:10	Crooks	Direct
honor rather	honorary	347:13	Crooks	Direct
Science	Sciences	347:16	Crooks	Direct
on transferase	on methyl transferases	348:18	Crooks	Direct
par amino	amino	348:20	Crooks	Direct
in	and	349:4	Crooks	Direct
in - I'm	in Asia I'm	349:9	Crooks	Direct
APS Pharma Cytek	AAPS PharmSciTech	349:12	Crooks	Direct
upstart up	up start-up	350:21	Crooks	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 15 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
clinic.	clinical studies.	351:1	Crooks	Direct
consult tan see	consultancies	351:8	Crooks	Direct
is one	is the one	353:13	Crooks	Direct
ethyl cyclic moiety, planar	Heterocyclic moiety, and a planar	355:2	Crooks	Direct
a C8	at the C8	355:4	Crooks	Direct
4 substituent	4-substituent	355:5	Crooks	Direct
ring that	ring, that	355:6	Crooks	Direct
hydroxy. Just	hydroxy, just	355:6	Crooks	Direct
had a 9	had at the 9	355:8	Crooks	Direct
at the	an	355:9	Crooks	Direct
certain	structural	355:10	Crooks	Direct
SRA	SAR	356:19	Crooks	Cross
SRA	SAR	356:22	Crooks	Cross
chemistries	stereochemistries	357:5	Crooks	Cross
SRA	SAR	357:11	Crooks	Cross
5-5...tetracyclic	5,6...heterocyclic	357:22	Crooks	Cross
aeromatic and	aromatic ten	357:23	Crooks	Cross
aeromatic	aromatic	357:24	Crooks	Cross
C-9 and	C-9, an	358:2	Crooks	Cross
aeromatic	aromatic	358:8	Crooks	Cross
aeromatic	aromatic	358:11	Crooks	Cross
principal	? ring	359:15	Crooks	Cross
it's a	it's the one	359:16	Crooks	Cross
should	shouldn't	359:19	Crooks	Cross
said, the central element	said, was the structural element	361:23	Crooks	Cross
a razor erase	an eraser and erase	363:19	Crooks	Cross
as	has	363:25	Crooks	Cross
structural	the structural	364:1	Crooks	Cross
core	carbon	364:9	Crooks	Cross
clear	clever	364:16	Crooks	Cross
module	moiety	364:18	Crooks	Cross
aeromatic model	aromatic moiety	364:19	Crooks	Cross
aeromatic	aromatic	364:20	Crooks	Cross
think has	think what has	368:4	Crooks	Cross
natural	nitrogen	368:13	Crooks	Cross
IBMX.	IBMX analogs.	369:3	Crooks	Cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 16 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
That - as	That - has a	370:10	Crooks	Cross
flexible benefit sill group is compared with a rotational	flexible benzyl group compared with a rotationally	370:11	Crooks	Cross
Fixed benefit sill	Fixed benzyl	370:12	Crooks	Cross
world.	work.	371:4	Crooks	Cross
structural	structure	371:23	Crooks	Cross
Well, the results for this 184 hydroxy phenylthio	Well, the results for this 8-4 hydroxy phenyl-thio	372:6	Crooks	Cross
184	C8 4-	372:6	Crooks	Cross
compound.	compounds.	371:18	Crooks	Cross
IBMX.	IBMX compounds.	373:2	Crooks	Cross
out activity	out structure activity	373:6	Crooks	Cross
84	8 dash 4	373:9	Crooks	Cross
hydroxyl phenylthio	4-hydroxyphenylthio	373:10	Crooks	Cross
our in	our own in	373:14	Crooks	Cross
Structural-activity	Structure-activity	374:7	Crooks	Cross
SAR....and	an SAR.....as	374:16	Crooks	Cross
an ischemic run	a ? compound	374:21	Crooks	Cross
end	n	375:3	Crooks	Cross
CA	C-8	375:6	Crooks	Cross
confirmation	conformation	379:18	Crooks	Redirect
cooks	Crooks	383:17	Crooks	Redirect
confirmation	conformation	383:17	Crooks	Redirect
"Answer: Sir, my name is Richard Labaudiniere."	A. So my name is Richard Laubaudiniere.	389:20	Labaudiniere	designations
lists of number	lists of compounds	390:21-22	Labaudiniere	designations
compound	compounds	391:1	Labaudiniere	designations
compound	compounds	391:2	Labaudiniere	designations
"Question: --diagrams of those same compound? Answer: That's the structure of the compound, yes."	Q. --diagrams of those same compounds? A. Those are the structures of the compounds, yes.	391:1-3	Labaudiniere	designations
"Question: When did you give him that list of compounds? This spring?	Q. When did you give him that list of compounds to screen?	391:8-9	Labaudiniere	designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 17 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
compounds? This spring	compounds this spring?	391:9	Labaudiniere	designations
PDE-5, the PDE-5	PDE-V, the PDE-V	392:19	Labaudiniere	designations
Projects that our chemists	Project that's - -our chemists	393:12	Labaudiniere	designations
In general?	general?	394:4	Labaudiniere	designations
PDE-5	PDE-V	394:8	Labaudiniere	designations
"Question: From 1991-1994 when you were there, what was the greatest number of chemists?"	Q. From 1991-1994 when you were there, what was the greatest number of scientists?	394:25-395:1	Labaudiniere	designations
chemists	scientists	395:1	Labaudiniere	designations
were two	was two	395:16	Labaudiniere	designations
PDE-5	PDE-V	396:2	Labaudiniere	designations
No, biochemist	No. Biochemist	396:15	Labaudiniere	designations
PDE-5	PDE-V	397:4	Labaudiniere	designations
PDE-5	PDE-V	397:17	Labaudiniere	designations
Glaxo?	Glaxo--	398:11	Labaudiniere	designations
Yeah.	yeah?	398:13	Labaudiniere	designations
go	know	398:17	Labaudiniere	designations
analogues	analogs	398:20	Labaudiniere	designations
1989	1990	400:22	Labaudiniere	designations
you have been handed what has	I have handed you what's	400:17-18	Labaudiniere	designations
"Question: --which is a cardiovascular discovery grant annual report 1989 to 1989 from Dr. Corbin	which is a cardiovascular discovery grant annual report 1989 to 1990 from Doctor Corbin	400:21-22	Labaudiniere	designations
analogues	Analogs	400:24	Labaudiniere	designations
you have	you've	401:1	Labaudiniere	designations
analogues	analogs	401:4	Labaudiniere	designations
update, November 2, 1990 cardiovascular discovery grant progress report	Update November 2, 1990 Cardiovascular Discovery Grant Progress Report.	401:9-10	Labaudiniere	designations
analogues	analogs	401:14	Labaudiniere	designations
Glaxo Inc.	Glaxo, Inc.	401:21	Labaudiniere	designations
you look	you'd look	402:11	Labaudiniere	designations
are there any	are any	402:12	Labaudiniere	designations
worked on?	worked on?	402:15	Labaudiniere	designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 18 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
report,	report--	403:1	Labaudiniere	designations
inhibitors	Inhibitors	405:6	Labaudiniere	designations
phosphodiesterase,	phosphodiesterase,"	405:7	Labaudiniere	designations
'we	We	405:8	Labaudiniere	designations
molecule.'	molecule."	405:12	Labaudiniere	designations
why	in	405:25	Labaudiniere	designations
"Answer: At the time of the visit of Dr. Corbin?"	A. At the time of the visit of Dr. Corbin.	407:6-7	Labaudiniere	designations
the	a	407:14	Labaudiniere	designations
to your	or the	408:9	Labaudiniere	designations
analogues	analogs	408:14	Labaudiniere	designations
analogues	analogs	408:23	Labaudiniere	designations
It's	It is	409:8	Labaudiniere	designations
that the	at the	409:17	Labaudiniere	designations
address	addressees	409:18	Labaudiniere	designations
committee: is	Committee. Is	409:20	Labaudiniere	designations
for collaboration	for a collaboration	409:24	Labaudiniere	designations
type 5 PDE	type V PDE	410:14	Labaudiniere	designations
PDE-5	PDE-V	410:18	Labaudiniere	designations
interest: isn't	interest. Isn't	410:19	Labaudiniere	designations
PDE-5	PDE-V	410:22	Labaudiniere	designations
Yes. Yes.	Yes.	410:24	Labaudiniere	designations
that	at	411:1	Labaudiniere	designations
PDE-5	PDE-V	411:4	Labaudiniere	designations
record	remember	411:6	Labaudiniere	designations
the	a	411:10	Labaudiniere	designations
Is it fair	Fair	411:14	Labaudiniere	designations
being discussion	being a discussion	411:18	Labaudiniere	designations
reads, quote, Results	reads, "Results	412:1	Labaudiniere	designations
program, end quote	program"	412:3	Labaudiniere	designations
quote, directed	directed	412:4	Labaudiniere	designations
failure, end quote	Failure	412:5	Labaudiniere	designations
parentheses, end parentheses	(Paris)	413:15	Labaudiniere	designations
C G	cG	413:16	Labaudiniere	designations
quote our collaboration, end quote.	our collaboration.	415:1	Labaudiniere	designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 19 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
PDE-5	PDE-V	416:1	Labaudiniere	designations
what has	what's	416:9	Labaudiniere	designations
That's Plaintiff's 231 and already evidence.	Mr. Rommel: That's Plaintiff's 231 and already evidence.	416:10	Labaudiniere	designations
It's a	which is a	416:10	Labaudiniere	designations
analogues	Analogs	416:18	Labaudiniere	designations
which is Plaintiff's 253 and has not been admitted,	Rommel: Which is plaintiff's 253 and has not been admitted.	417:2-3	Labaudiniere	designations
You do	Do you	418:2	Labaudiniere	designations
have not	were not	418:10	Labaudiniere	designations
Why didn't you use any of the data?	You didn't use any of the data?	418:11	Labaudiniere	designations
Missing section	Question: What do you mean by that? (This goes after the line "You didn't use any of the data?" and before the line "We are not working on IBMX analogues.")	418:11-12 (?)	Labaudiniere	designations
"Answer: We are not working on IBMX analogues.	A. We were not working on IBMX analogues.	418:12	Labaudiniere	designations
analogues	analogs	418:12	Labaudiniere	designations
34 and 35, which	Rommel: Which are Plaintiff's 374 and 375 and Joint Exhibit 29 and 4, both which are in evidence, your Honor.	419: 1-3	Labaudiniere	designations
this	thus	419:11	Labaudiniere	designations
worked	work	420:9	Labaudiniere	designations
assay, the compound.	assay the--the compounds.	420:11	Labaudiniere	designations
compound.	compounds.	420:11	Labaudiniere	designations
groups.	group.	420:19	Labaudiniere	designations
had his	were in his	420:19-20	Labaudiniere	designations
GR340X	GR 30040x	420:25-421:1	Labaudiniere	designations
What did that contribute to the discovery of tadalafil?	How did that contribute to the discovery of tadalafil?	421:2-3	Labaudiniere	designations
appeared	appears	421:7	Labaudiniere	designations
analogues.	analogs.	421:9	Labaudiniere	designations
formed	found	421:17	Labaudiniere	designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 20 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
PDE-5	PDE-V	422:10	Labaudiniere	designations
not really looking like other PDE-5	not really looking like other inhibitors of PDE V	422:10-11	Labaudiniere	designations
PDE-5	PDE-V	422:11	Labaudiniere	designations
PDE-5	PDE-V	422:13	Labaudiniere	designations
PDE-5	PDE-V	422:16	Labaudiniere	designations
to identify new pharmacoform	to identify new pharmacophore	422:24	Labaudiniere	designations
PDE-5	PDE-V	422:25	Labaudiniere	designations
vaso relaxer	vasorelaxer	423:5	Labaudiniere	designations
PDE-5	PDE V	423:17	Labaudiniere	designations
I've	I have	423:17	Labaudiniere	designations
to human	to the use of the human	424:1	Labaudiniere	designations
assay	SAR	424:7-8	Labaudiniere	designations
I'd like	Like	424:11	Labaudiniere	designations
No. 34, and	Rommel: And that is Plaintiff's 374, Joint 29, which is already in evidence.	424:12-13	Labaudiniere	designations
evidence. That's	Evidence. - - that's	424:13	Labaudiniere	designations
modification of the C5 position	"Modification at the C5 Position"	424:15-16	Labaudiniere	designations
GR 340	GR 30040x	425:9	Labaudiniere	designations
between chemists. You know myself and Alain.	between chemists, you know. Myself and Alain.	425:13	Labaudiniere	designations
remember. You know.	remember, you know.	425:18	Labaudiniere	designations
go	no	426:7	Labaudiniere	designations
But in the	But beginning,	426:13	Labaudiniere	designations
data. You	data, you	426:14	Labaudiniere	designations
GR 340	GR 30040x	426:23-24	Labaudiniere	designations
the high Dan to within series	the hydantoin series	427:2	Labaudiniere	designations
correct?	right?	427:2	Labaudiniere	designations
terms	Term	427:7	Labaudiniere	designations
are	were	427:9-10	Labaudiniere	designations
are	were	427:17	Labaudiniere	designations
at the time; journals?	at the time? Journals?	427:22	Labaudiniere	designations
common	common	428:6	Labaudiniere	designations
will - will - will	will -- will	428:7	Labaudiniere	designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 21 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
who	that	429:9	Labaudiniere	designations
Term of chemistry	In terms of chemistry	429:16	Labaudiniere	designations
undergo	understanding	430:1	Labaudiniere	designations
yeah. Every	yeah, every	430:4	Labaudiniere	designations
registered	registered	430:6	Labaudiniere	designations
in	at	430:16	Labaudiniere	designations
you've	you have	430:20	Labaudiniere	designations
yourself, at	yourself at	431:22	Labaudiniere	designations
a	the	431:23	Labaudiniere	designations
You	Do you	432:1	Labaudiniere	designations
tech substructure.	particular substructure.	432:11-12	Labaudiniere	designations
substructure. What is it	substructure. What is it that	432:14	Labaudiniere	designations
a core structure. What	a "core structure", what	432:17	Labaudiniere	designations
substructure	structure	432:24	Labaudiniere	designations
one. And	one, and	433:1	Labaudiniere	designations
an	and	433:2	Labaudiniere	designations
other-where you have structure, chemical structure	structure, chemical structure,	433:8	Labaudiniere	designations
local?	local	433:11	Labaudiniere	designations
do searches	do a search	433:20	Labaudiniere	designations
analogues	analogs	434:3	Labaudiniere	designations
especially the global database	especially with the global database	434:13	Labaudiniere	designations
no, you don't have to do that	no, you don't do that	434:20-21	Labaudiniere	designations
an	and	434:21	Labaudiniere	designations
you do that.	you do that,	434:22	Labaudiniere	designations
But	but	434:23	Labaudiniere	designations
when you had were already	when you were already	435:3-4	Labaudiniere	designations
"Answer: Beginning a new program?	A. Beginning a new program.	435:5	Labaudiniere	designations
new program	new program	435:6	Labaudiniere	designations
targets. That's	targets, that's	435:10	Labaudiniere	designations
under way	underway	435:13	Labaudiniere	designations
was basically	was to - basically	435:13	Labaudiniere	designations
One of my rolls	One of my roles	436:5	Labaudiniere	designations
was to was to prospect	was to prospect	436:5-6	Labaudiniere	designations
advance	advance	436:12	Labaudiniere	designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 22 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
Do	To	436:13	Labaudiniere	designations
identify	identified	436:18-19	Labaudiniere	designations
analogues	analogs	437:3	Labaudiniere	designations
question. As	question, as	437:5	Labaudiniere	designations
became	become	437:6	Labaudiniere	designations
global date database	global database	437:11	Labaudiniere	designations
database that	database system that	437:22	Labaudiniere	designations
to do a search	to search	438:5	Labaudiniere	designations
for the	for a	438:6	Labaudiniere	designations
Was it only - because	Because	438:10	Labaudiniere	designations
did	would	438:16	Labaudiniere	designations
it's - it's -it's a	it's depository	438:22	Labaudiniere	designations
the	a	440:3	Labaudiniere	designations
screening for search	screen for search	440:7-8	Labaudiniere	designations
searchable the	searchable in	440:22	Labaudiniere	designations
Which is, I believe, Defendant's Exhibit SU,	Rommel: Which is, I believe, Defendant's Exhibit SU.	441:8-9	Labaudiniere	designations
to page 16455. I'm sorry. Strike	--to Page 16455 - I'm sorry, strike	441:9	Labaudiniere	designations
tetra-hydro-beta	tetrahydro-beta	442:15	Labaudiniere	designations
tetra-hydro-beta	tetrahydro-beta	442:16	Labaudiniere	designations
tetra-hydro-beta	tetrahydro-beta	442:21	Labaudiniere	designations
It's on GLAX-164455.	It's on GLAX16455.	443:4	Labaudiniere	designations
you are	you're	445:7	Labaudiniere	designations
RMC	"RMC	445:9	Labaudiniere	designations
agreement	agreeing	445:10	Labaudiniere	designations
professor	Professor	445:10	Labaudiniere	designations
kinase stimulation.	Kinases Stimulation.	445:11	Labaudiniere	designations
the	that	445:24	Labaudiniere	designations
Beta-Carbolines	B-Carbolines	446:25	Labaudiniere	designations
seen?	seen.	447:20	Labaudiniere	designations
document.	document before.	451:4	Fegerson	designations
No. 100 - Plaintiff's Exhibit 406	No. 100 - Rommel: Plaintiff's Exhibit 406.	454:1	Fegerson	designations
Glaxo Group, Inc.	Glaxo Inc.	454:2	Fegerson	designations
right corner	right-hand corner	455:18	Fegerson	designations
Ferguson - designations	Ross-designations	458	Fegerson	designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 23 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 8, 2008 (D.I. 141)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
Ferguson - designations	Ross-designations	459	Fegerson	designations
Ferguson - designations	Ross-designations	460	Fegerson	designations
Ferguson - designations	Ross-designations	461	Fegerson	designations
Ferguson - designations	Ross-designations	462	Fegerson	designations
Shaffer	Schafer	462:17	Fegerson	designations
period.	period?	463:3	Fegerson	designations
Ferguson - designations	Ross-designations	463	Fegerson	designations
Ferguson - designations	Ross - designations	464	Fegerson	designations
Ferguson - designations	Ross - designations	465	Fegerson	designations
Ferguson - designations	Ross -designations	466	Fegerson	designations
Ferguson - designations	Ross - designations	467	Fegerson	designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 24 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 9, 2008 (D.I. 142)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
George	Jorge	473:13	Grondin	Direct
CLE miss tree	chemistry	483:18	Grondin	Direct
attest	a test	488:4	Grondin	Direct
De luz	Toulouse	520:10	Grondin	Cross
relayed	related	521:13	Grondin	Cross
de Luz	Toulouse	522:1	Grondin	Cross
de Luz	Toulouse	522:3	Grondin	Cross
Brodet	Baudet	527:4	Grondin	Cross
wept	went	531:20	Grondin	Cross
no	know	532:9	Grondin	Cross
way	weigh	532:23	Grondin	Cross
values	values	544:9	Grondin	Cross
values	values	545:3	Grondin	Cross
data	data	562:16	Grondin	Cross
your	you're	565:8	Grondin	Cross
proceed seeding	preceeding	565:13	Grondin	Cross
phosphenylation	phosphorylation	571:3	Grondin	Cross
that is	is it	575:22	Ross	Designations
or	and	576:23	Ross	Designations
kinase and	kinase. And	576:25	Ross	Designations
reserve	research	578:9-10	Ross	Designations
lab	lab's	581:12	Ross	Designations
other projects to consider	Other Projects to Consider	582:9	Ross	Designations
maim	male	582:17	Ross	Designations
treat maim male impotence	treat male impotence	582:22	Ross	Designations
his - his thoughts	his thoughts	583:18	Ross	Designations
to a continue - - to continuing	to continuing	584:3	Ross	Designations
it.	itself.	584:9	Ross	Designations
Jackie core bins	Jackie Corbin's	584:12	Ross	Designations
recollection	Memory	584:18	Ross	Designations
I'm parting	imparting	585:16	Ross	Designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 25 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 9, 2008 (D.I. 142)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
Fax	fax	589:3	Ross	Designations
compared ...Fax	compare it....fax	589:4	Ross	Designations
Fax	fax	589:5	Ross	Designations
There's	There is	590:3	Ross	Designations
reach	reason	590:8	Ross	Designations
quote, this .....collaboration, end quote.	"this .....collaboration."	590:13-14	Ross	Designations
And in my mind, in	an-- in	591:10	Ross	Designations
class action	collaboration	592:20	Ross	Designations
quote the proposals.....process, end quote.	"the proposal is ....process."	593:14	Ross	Designations
"Question: Could you look at Exhibit 604	Q. Could you look at Exhibit 64	594:18	Ross	Designations
The first is Alain.	The first is Alain Daugan?	597:2	Ross	Designations
'960	960	597:6	Ross	Designations
which we have already been through.	Mr. Rommel: Which we have already been through.	600:12-13	Kadouri	Designations
name Anis	name is Anis	600:16	Kadouri	Designations
we could now	we now	604:12	Kadouri	Designations
range GLAX-036341	ranged GLAX 03641	605:6	Kadouri	Designations

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 26 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
they're	there are	609:16	Kadouri	Designation
Dr. Kadouri, before	Before	613:2	Kadouri	Designation
Glaxo- - strike that	Glaxo - - excuse me strike that.	613:4	Kadouri	Designation
An	And	613:11	Kadouri	Designation
And what	What	613:18	Kadouri	Designation
data bases	databases	614:19	Kadouri	Designation
in.	in?	614:21	Kadouri	Designation
what has	what's	614:23	Kadouri	Designation
previously been	been previously	614:24	Kadouri	Designation
198, which	198. Mr. Rommel: Which	614:24	Kadouri	Designation
have the	have a- -	615:15	Kadouri	Designation
pick up	purpose	615:15	Kadouri	Designation
sin they sighs	synthesis	616:4	Kadouri	Designation
fill	filled	616:5	Kadouri	Designation
registration stuff	registration staff	617:25	Kadouri	Designation
position	information	618:2	Kadouri	Designation
about new	about each new	618:2	Kadouri	Designation
would a numb assigned	would a number be assigned	618:6	Kadouri	Designation
possible exhibits	possibilities	618:10	Kadouri	Designation
novel, no. It	novel. No, it	618:11	Kadouri	Designation
registration stuff	registration staff	618:13	Kadouri	Designation
do event	does not	618:15	Kadouri	Designation
has benefit already benefit	has been already has been	618:20	Kadouri	Designation
registration stuff	registration staff	618:21	Kadouri	Designation
number. The	number, the	618:21	Kadouri	Designation
hear	higher	619:8	Kadouri	Designation
later in team	later in time	619:9	Kadouri	Designation
team	time	619:9	Kadouri	Designation
France. It	France, it	620:4	Kadouri	Designation
GF. With	GF, with	620:5	Kadouri	Designation
GR -- no	GR. No	620:9	Kadouri	Designation

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 27 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
alphabetical designating	alphabetical designation	620:10	Kadouri	Designation
designating	designation	620:10	Kadouri	Designation
"Answer: Answer. Glax.	A. Glax	621:10	Kadouri	Designation
everybody	has been	621:11	Kadouri	Designation
"Question: There everybody references in some of the documents to Glax data bank.	Q. There has been references in some of the documents to something called Glaxdatabank.	621:11-12	Kadouri	Designation
database in	database to which he -- in	621:16	Kadouri	Designation
the	this	621:23	Kadouri	Designation
resolved.	evolved.	622:4	Kadouri	Designation
resolved	evolved	622:4	Kadouri	Designation
It kept	It's kept	622:5	Kadouri	Designation
we've that we've looked	that we have looked	622:12	Kadouri	Designation
There's	There is	622:12	Kadouri	Designation
gave and it	gave for a database, and the acronym stands for	622:19	Kadouri	Designation
chloro	color	623:2	Kadouri	Designation
allow	allows	623:9	Kadouri	Designation
ascertain this	ascertain that this	623:9	Kadouri	Designation
have a unique reference	has a unique number, reference	623:13	Kadouri	Designation
that	any	623:16	Kadouri	Designation
What	Was	623:17	Kadouri	Designation
"Answer: A lab notebook reference.	A. I mean, a lab reference is the lab notebook reference.	624:1	Kadouri	Designation
A lab notebook reference	I mean, a lab reference is the lab notebook reference.	624:1	Kadouri	Designation
for	or	624:2	Kadouri	Designation
identified by	identified as --	624:5	Kadouri	Designation
main taped locally	maintained locally	625:19	Kadouri	Designation

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 28 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
main taped	maintained	625:19	Kadouri	Designation
Les Ulis	Les Ulis,	625:21	Kadouri	Designation
database.	databases?	626:3	Kadouri	Designation
we started moving	we shifted to - started moving	626:8	Kadouri	Designation
Isis base	IsisBase	626:11	Kadouri	Designation
Isis base	IsisBase	626:17	Kadouri	Designation
search the Glax database	search the Glaxdatabank	627:19	Kadouri	Designation
Isis base	IsisBase	628:22	Kadouri	Designation
base after that	Base after that was - after that	628:23	Kadouri	Designation
Isis base	IsisBase	628:24	Kadouri	Designation
we also have the	we have also the	629:5	Kadouri	Designation
I mean, and the type of	I mean. Any type of	629:7	Kadouri	Designation
and the	any	629:7	Kadouri	Designation
alpha numeric	alphanumeric	631:21	Kadouri	Designation
You can	You could	632:1	Kadouri	Designation
"Question: You can search, for example, by inhibition data?	Q. You could search, for example, for inhibition data?	632:1-2	Kadouri	Designation
have not	haven't	632:9	Kadouri	Designation
have not	haven't	632:22	Kadouri	Designation
searches, printouts	searches, be - printouts	632:25	Kadouri	Designation
We've been	Let's - we have been	633:1	Kadouri	Designation
they've	they have	633:7	Kadouri	Designation
indicate	Kate	633:18	Kadouri	Designation
separate, but at the time	separate, but the - they - at the time	633:23	Kadouri	Designation
database	databank	634:9	Kadouri	Designation
drew	draw	635:25-636:1	Kadouri	Designation
that	there	635:2	Kadouri	Designation
Did you	You	635:10	Kadouri	Designation
Yes, it is.	Yes, this is it.	635:16	Kadouri	Designation

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 29 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
searched or the	searches are -or the	636:6	Kadouri	Designation
Exhibit No. 200.	Exhibit No. 200, which is a ChemBase Manual.	637:1	Kadouri	Designation
two	201	638:13	Kadouri	Designation
Isis base	ISISBase	640:23-24	Kadouri	Designation
"Answer: In input on a keyboard.	A. Input on a keyboard.	640:9	Kadouri	Designation
Kadorui	Kadouri	643:12	Konjeti	Direct
secretary car	Sekhar	644:10	Konjeti	Direct
Radiation	Radiation Oncology	645:16	Konjeti	Direct
Vanderbilt	Andhra	646:16	Konjeti	Direct
Mangelor	Mangalore	646:19	Konjeti	Direct
chemist. We	chemist who	647:6	Konjeti	Direct
cyclic GMP, do test on smooth muscle	cyclic GMP analogs to test on smooth muscle	647:7	Konjeti	Direct
indol, which is presented in a lot of	indole, which is present in lots of	647:16	Konjeti	Direct
using in doll as a test model and I have several groups of	using indole as a parent molecule and I have attached several heterocyclic groups	647:19	Konjeti	Direct
indol that - - studied that.	indole and studied their biological activity.	647:20	Konjeti	Direct
study	research	648:4	Konjeti	Direct
undergo	understanding	648:21	Konjeti	Direct
compound	compounds	649:15	Konjeti	Direct
8 naphthyl cGMP	8 naphthyl thio cGMP	649:19	Konjeti	Direct
shorthand variety for the ribose cyclic	short way for the ribose cyclic	649:24	Konjeti	Direct
octobromo, an entire cGMP.	ortho bromo phenylthio cGMP	650:6	Konjeti	Direct
conferences was attended	compounds were synthesized	650:19	Konjeti	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 30 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
cGMP and the compounds for relaxation	cGMP kinase and for relaxation	650:20	Konjeti	Direct
8-naphtyl cGMP. And the tenth compound is 8-Octobromo for this cGMP.	8-naphthylthio-cGMP. And the tenth compound is 8-ortho bromo phenylthio- cGMP.	650:24	Konjeti	Direct
simply	same	651:6	Konjeti	Direct
It's 8-4hydrochloro cGMP	It's is 8-4-chlorophenylthio-cGMP	652:3	Konjeti	Direct
compounds we already	compounds we already tested	652:4	Konjeti	Direct
About	Above	653:7	Konjeti	Direct
one 20446A	GI120446A	653:11	Konjeti	Direct
8-octobromothio cGMP	8-bromophenylthio cGMP	653:21	Konjeti	Direct
hydroxythio	hydroxyphenylthio	654:8	Konjeti	Direct
140446A, which was a proposal	120446A which was proposed	654:20	Konjeti	Direct
8-octobromophenylthio cGMP	8-ortho bromophenylthio cGMP	656:23	Konjeti	Direct
8-methylthiono cGMP	8-naphthylthio cGMP	656:24	Konjeti	Direct
article	art	658:9	Konjeti	Direct
activity	radioactivity	659:22	Konjeti	Direct
and	in	659:23	Konjeti	Direct
Analyzing the program,	Analysis of the date using computer program	660:5	Konjeti	Direct
reactive	active	660:6	Konjeti	Direct
drug concentrations we used, and the drug program with the graph	drug concentrations they used, and the computer program generated the	660:15	Konjeti	Direct
from	on	660:22	Konjeti	Direct
yank	end	662:18	Konjeti	Direct
the grant would be end.	the grant was going to end.	662:19	Konjeti	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 31 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
getting more. And this always helps, with new results	getting it renewed. And it always helps to have new results	662:21-22	Konjeti	Direct
have some problems if their	have some problems, their	662:24	Konjeti	Direct
that	their	663:10	Konjeti	Direct
It's commercially well-known, and Dr.	It's commercially available, well-known inhibitor, and Dr.	663:13	Konjeti	Direct
had made some compounds with the IBMX analogs and tested	had made 8-subsituted compounds with IBMX and tested	663:15	Konjeti	Direct
That is one of the substitutions,	That is one of the phenylthio substitutions,	663:24	Konjeti	Direct
muscle relaxation	muscle relaxant	663:25	Konjeti	Direct
substance	substitution	664:1	Konjeti	Direct
more efficient on one and two operations of	modification on one and two positions of	664:6	Konjeti	Direct
position in the high butyl groups, like phenyl groups,	Position with the bulky groups, like phenylthio groups	664:8	Konjeti	Direct
are	have	664:10	Konjeti	Direct
sync.	syn.	664:12	Konjeti	Direct
This is the cyclic molecule. This is ribose cyclic on	This is the cyclic GMP molecule. This is ribose cyclic phosphate on	665:23	Konjeti	Direct
84	8,4	666:11	Konjeti	Direct
rare	where	666:17	Konjeti	Direct
p.m.	MP	667:6	Konjeti	Direct
synthesize	synthesized	668:2	Konjeti	Direct
catalytic PDE-5	catalytic site on PDE-5	668:13	Konjeti	Direct
and PDE on Page four	and PDE inhibitors on	669:7	Konjeti	Direct
84	8,4	669:11	Konjeti	Direct
benzamidazole	benzyl	676:1	Konjeti	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 32 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
Substitution at the benzyl group, which is presented in 84	Substitution with benzyl group, which is present in 8 4-	676:13	Konjeti	Direct
hydroxyl phenyltio	Hydroxyl phenylthio	676:14	Konjeti	Direct
8H4123	AH4123	680:8	Konjeti	Direct
1501	151	682:17	Konjeti	Direct
of benzyl compound (indicating).	with benzyl substitution	683:13	Konjeti	Direct
GFX66023X	GR 66023X	687:15	Konjeti	Direct
GFX66775X	GR 66775X	687:23	Konjeti	Direct
GFX68801X	GR 68801X	688:8	Konjeti	Direct
GFX89359X	GR 89359X	688:17	Konjeti	Direct
give	gave	692:8	Konjeti	Direct
give	gave	693:2	Konjeti	Direct
give	gave	694:16	Konjeti	Direct
8, 2 - phenylthio cGMP	8-2-aminophenylthio	694:17	Konjeti	Direct
8-bromo-N cGMP	8 -bromo-PET-cGMP	695:2	Konjeti	Direct
824 hydroxy	8 2, 4-dihydroxy	700:11	Konjeti	Direct
IBM Isis	IBMX's	702:14	Konjeti	Direct
since Glaxo	by Glaxo	709:11	Konjeti	Direct
wants	owns	709:19	Konjeti	Direct
Konheti	Konjeti	712	Konjeti	Cross
PDE-5 at	PDE-5 assay at	716:8	Konjeti	Cross
84 hydroxy phenylthio IBMX	8-4 hydroxy phenylthio IBMX	716:19	Konjeti	Cross
84	8,4	716:19	Konjeti	Cross
with PDE-5 cGMP	for PDE-5 inhibition	722:7	Konjeti	Cross
GFX77123	GR 77123	723:4	Konjeti	Cross
exhibit 2	exhibit 22	724:4	Konjeti	Cross
exhibit 2	exhibit 22	724:5	Konjeti	Cross
PGK	PKG	727:14	Konjeti	Cross
PGK.	PKG	727:15	Konjeti	Cross
GFX65357	GR 65357	728:17	Konjeti	Cross
AH2095	AH20905	729:19	Konjeti	Cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 33 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
1405	145	732:19	Konjeti	Cross
G.I. 99546A	GI99546A	733:8	Konjeti	Cross
GR37539	GR37539X	733:14-15	Konjeti	Cross
GR 63184	GR63184A	733:22	Konjeti	Cross
G.I. 122699X	GI122699X	734:6	Konjeti	Cross
north	our other	739:7	Konjeti	Cross
Grodin	Grondin	739:22	Konjeti	Cross
Grodin	Grondin	740:10	Konjeti	Cross
exponential	experimental	741:5	Konjeti	Cross
issued	received	741:24	Konjeti	Cross
Formula 1	Formula I	744:9	Konjeti	Cross
Formula 1	Formula I	744:12	Konjeti	Cross
former 1	Formula I	744:17	Konjeti	Cross
former	formula	744:17	Konjeti	Cross
Formula 1	Formula I	744:21	Konjeti	Cross
object	on	745:10	Konjeti	Cross
exhibits	existing inhibitors	746:11	Konjeti	Cross
ragos	ribose	749:2	Konjeti	Cross
ragos	ribose	749:2	Konjeti	Cross
ragos	ribose	749:3	Konjeti	Cross
ragos	ribose	749:3	Konjeti	Cross
ragos	ribose	749:4	Konjeti	Cross
pending grasp	appending groups	749:16	Konjeti	Cross
pending grasp	appending groups	749:16	Konjeti	Cross
zaprisant	zaprinast	749:20	Konjeti	Cross
that are	that we are	749:24	Konjeti	Cross
bag	back	752:24	Konjeti	Cross
zaprisant	zaprinast	752:24	Konjeti	Cross
Konheti	Konjeti	754	Konjeti	Cross
Konheti	Konjeti	755	Konjeti	Cross
Konheti	Konjeti	756	Konjeti	Cross
to a five-membered ring	fused to a five-membered ring	756:14	Konjeti	Cross
Konheti	Konjeti	757	Konjeti	Cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 34 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
Konheti	Konjeti	758	Konjeti	Cross
Biology	Editorial	762:1	Francis	Direct
Biochemistry	Biological Chemistry	762:2	Francis	Direct
have	had	762:23	Francis	Direct
that primarily	that by primarily	762:24	Francis	Direct
AMP	cyclic GMP and PKG	763:16	Francis	Direct
PKG once	GMP analogs	763:18-19	Francis	Direct
tracheales	trachealis	764:1	Francis	Direct
relaxing	relaxed	764:11	Francis	Direct
are	using	764:17	Francis	Direct
that some	that for some	765:6	Francis	Direct
resistantphosphodiesterases	Resistant to phosphodiesterases	765:14	Francis	Direct
of, thiopho electron	inhibitor, theophylline	766:7	Francis	Direct
and still	and is still	766:9	Francis	Direct
various like asthma. Whether it is actions through the	various ailments like asthma. Whether its actions are through the	766:10	Francis	Direct
well-established, to	well-established to	769:7	Francis	Direct
bounded	bound cGMP	770:9	Francis	Direct
that came off, it	that molecule came off PDE5, it	770:11	Francis	Direct
five prime GMP	5'-GMP	770:12	Francis	Direct
name	named	770:21	Francis	Direct
effect tours	effectors	771:7	Francis	Direct
in this current topics and	In Current Topics and in Cellular Regulation	771:13-14	Francis	Direct
physed	best	771:19	Francis	Direct
MB	MD	772:25	Francis	Direct
theme	scheme	773:4	Francis	Direct
Methods and Enzymology	Methods of Enzymology	773:5	Francis	Direct
art	artery	776:19	Francis	Direct
Cyclonucleotide	Cyclicnucleotide	779:12	Francis	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 35 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 10, 2008 (D.I. 143)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page/Line Nos	Witness	Examination Type
be	we	783:1	Francis	Direct
instructed	constructed	784:17	Francis	Direct
cow molecule	camodulin	786:8-9	Francis	Direct
as	[delete as]	786:15	Francis	Direct
IBM examination	IBMX molecule	786:21	Francis	Direct
CKP	CPK	787:13	Francis	Direct
combination	conformation	788:17	Francis	Direct
confirmation	conformation	790:2	Francis	Direct
motors	inhibitors	790:3	Francis	Direct
cyclic, ribose	cyclic ribose	790:7	Francis	Direct
that ribose…phosphate, it cannot	that the ribose….phosphate cannot	791:4	Francis	Direct
polymer	pocket	791:15	Francis	Direct
binding of sites	binding sites	792:7	Francis	Direct
assure	a sure	793:10	Francis	Direct
give an	giving	793:11	Francis	Direct
lab. Except	lab except	793:17	Francis	Direct
phenyl IBMX	phenylthio IBMX	794:16	Francis	Direct
CGBPMD	CG-BPDE	795:7	Francis	Direct
as	is	796:2	Francis	Direct
a plead	applied	798:12	Francis	Direct
arrows	arose	800:2	Francis	Cross
or	of	800:12	Francis	Cross
hydrolyzing,	hydrolyzing PDEs	801:19	Francis	Cross
what in….setting	what is in…..studying	801:22	Francis	Cross
nitric	nitric oxide	805:7	Francis	Cross
layout	late	808:23	Francis	Cross
Dr. Coe.	Dr. Koh	817:5	Francis	Cross
Coe	Koh	817:5	Francis	Cross
moment	momentum	817:8	Francis	Cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 36 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 11, 2008 (D.I. 144)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
M and B22,948	M & B 22,948	821:5	Francis	cross
M and B22,948	M & B 22,948	821:10	Francis	cross
onefold	hundred	823:4	Francis	cross
for	with	823:6	Francis	cross
CFD	PDE	823:21	Francis	cross
no	know	824:4	Francis	cross
of PDE-5	[delete of PDE-5]	825:3	Francis	cross
in the	[delete in the]	825:14	Francis	cross
isocy	isozyme	827:13	Francis	cross
Analogue	analogues	829:11	Francis	cross
hypothetical supportive suggested involved	"hypothetical," "supportive", "suggested", " involved"	831:22-23	Francis	cross
associated with, appears to be.	"associated with," "appears to be."	832:5	Francis	cross
the signal.....guanase and cyclic GMP.	the signal.....guanylylcyclase GMP.	832:6-9	Francis	cross
an	and	832:20	Francis	cross
setting studies	studying	833:6	Francis	cross
a comply	apply	833:18	Francis	cross
Barry Ross Exhibit LA was received into evidence?	Barry Ross received it?	839:19	Francis	cross
Exhibit 1 owe seven	Exhibit 107	840:2-3	Francis	cross
Q. Okay	A. Okay.	840:18	Francis	cross
Exhibit HL	Exhibit LH	842:24	Francis	cross
Exhibit HL	Exhibit LH	843:17	Francis	cross
(Exhibit HL was received into evidence.)	(Exhibit LH was received into evidence.)	844:18	Francis	cross
Cialis...they	Viagra...Bayer	845:4	Francis	cross
some active compound in	some of the active compound that is in	845:5	Francis	cross
triduum	tritium	845:13	Francis	cross
was	we	846:15	Francis	cross
fact.	fact witness.	847:10	Francis	cross
for	or	848:7	Francis	cross
PMG	5'-GMP	848:12	Francis	cross
cites	sites	848:18	Francis	cross
offending	affinity	848:18	Francis	cross
for	with	848:18	Francis	cross
offending	affinity	848:19	Francis	cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 37 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 11, 2008 (D.I. 144)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
Dorsey	du Orsay	854:8	Daugan	direct
university Dorsey	University du Orsay	854:10	Daugan	direct
Grondig	Grondin	861:16	Daugan	direct
Angela Degauville	Anne Charlotte de Gouville	861:19-20	Daugan	direct
GF 19690X	GF 196960X	862:25	Daugan	direct
Irena Dodock	Nerina Dodic	866:21	Daugan	direct
doctor due mate tremendous or doctor doe Dick	Dr. Dumaitre or Dr. Dodic	867:3	Daugan	direct
Kristoff	Christoph	867:13	Daugan	direct
Anin Panfenese	Annie Penfornis	867:19	Daugan	direct
substituted at position 4 with a hydroxy with a thio ether.	substituted at position 4 with a hydroxy and with a thio ether	872:21	Daugan	direct
A. Doctor, prior to this lawsuit, maybe it's obvious, but prior to this lawsuit, were you aware of the existence of a compound having the structure 8-4 hydroxy phenylthio IBMX?	Q. Doctor, prior to this lawsuit, maybe it's obvious, but prior to this lawsuit, were you aware of the existence of a compound having the structure 8-4 hydroxy phenylthio IBMX?	873:13-15	Daugan	direct
68 substituted IBMX analogues	six 8-substituted IBMX analogues	873:18-19	Daugan	direct
Formula 1	Formula I	874:16	Daugan	direct
Formula 1	Formula I	874:19	Daugan	direct
Formula 1	Formula I	874:24-25	Daugan	direct
Kristoff	Christoph	884:25	Daugan	direct
Kristoff	Christoph	885:4	Daugan	direct
half	have	886:6	Daugan	direct
an inhibition	and inhibition	890:7	Daugan	direct
GR3040	GR30040	891:9	Daugan	direct
tetrahydro-8-carboline	tetrahydro-beta-carboline	891:16	Daugan	direct
GR3040	GR30040	891:17	Daugan	direct
GR3040	GR30040	891:19	Daugan	direct
indolic	indole	897:2	Daugan	direct
GF1373770X	GF173770X	897:19	Daugan	direct
GLAX1701	GLAX17081	900:12	Daugan	direct
GD	GE	900:16	Daugan	direct
GLAX26365	GLAX00607	900:18	Daugan	direct
697	GF177697	901:19		direct
alarm	a large	904:4	Daugan	direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 38 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 11, 2008 (D.I. 144)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
Glax 4420	GLAX25440	904:22	Daugan	direct
displace two chiro center	displays two chiral centers, so	904:9	Daugan	direct
diesteryl isomers	diastereoisomers	904:11	Daugan	direct
960	GF196960	905:11	Daugan	direct
theories	series	909:18	Daugan	cross
GR3040	GR30040	919:6	Daugan	cross
GR3040	GR30040	935:5	Daugan	cross
try cyclic	tricyclic	935:19-20	Daugan	cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 39 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 14, 2008 (D.I. 145)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
CD K2	CDK2	949:24	Koh	Direct
a den know seen	adenosine	950:9	Koh	Direct
biorganic	bioorganic	952:2	Koh	Direct
biorganic	bioorganic	952:19	Koh	Direct
argument	activate or inhibit	954:7	Koh	Direct
Product	Products	955:5	Koh	Direct
Chemistry a	Chemistry A	955:7	Koh	Direct
are	on	955:13	Koh	Direct
biorganic	bioorganic	956:19	Koh	Direct
in	and	956:20	Koh	Direct
do	to	956:24	Koh	Direct
Grodin	Grondin	960:10	Koh	Direct
Grodin	Grondin	960:25	Koh	Direct
Grodin	Grondin	961:5	Koh	Direct
we	we	963:10	Koh	Direct
It	This	964:13	Koh	Direct
syn	down	965:22	Koh	Direct
to be add a ribose	[delete be]	966:5	Koh	Direct
CD kinase	cG-kinase	966:16	Koh	Direct
binded	binds	968:5	Koh	Direct
try neuro	Trifluoro	970:9	Koh	Direct
affected	affective	970:11	Koh	Direct
in know seen	inosine	970:23	Koh	Direct
sick like	cyclic	972:11-12	Koh	Direct
cH2	CH2	973:6	Koh	Direct
it	is	973:11	Koh	Cross
sulfur, what	sulfur for	973:12	Koh	Cross
Bioscience	Beilstein	974:18	Koh	Redirect
bioisis	bioisostere	979:14	Koh	Redirect
Bioisis. Sure, if it's a bioisis	Bioisostere. Sure, if it's a Bioisostere	979:24	Koh	Redirect
bioisis-steerism	bioisosterism	980:19	Koh	Redirect
KG	CG	982:1	Koh	Redirect
PDE	CGMP	982:24	Koh	Redirect
dipyrimadol	dipyridamole	984:15	Koh	Redirect
papervine	papaverine	984:15	Koh	Redirect
dipyrimadol, papervine	dipyridamole, papaverine	984:19	Koh	Redirect
dipyrimadol... papervine	dipyridamole.... papaverine	985:2	Koh	Redirect

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 40 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 14, 2008 (D.I. 145)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
cGMP	C	986:16	Koh	Redirect
Forumula 1	Formula I	986:16	Koh	Redirect
cGMP	C	986:18	Koh	Redirect
pyperasinedione	piperazinedione	986:21	Koh	Redirect
atom compound of	top compound is	987:5	Koh	Redirect
indol	indole	987:6	Koh	Redirect
PDE cGMP	PET-CGMP	987:12	Koh	Redirect
8,4-hydroxyphenyl IBMX	8-(4-hydroxy-phenylthio)-IBMX	989:9	Koh	Redirect
Grodin	Grondin	990:20	Koh	Redirect
8,4-hydroxyphenylthio IBMX	8-(4-hydroxy-phenylthio)-IBMX	991:4	Koh	Redirect
8,4-hydroxyphenylthio IBMX	8-(4-hydroxy-phenylthio)-IBMX	992:11	Koh	Redirect
just about --	just about anything --	992:17	Koh	Redirect
8,4-hydroxyphenylthio IBMX	8-(4-hydroxy-phenylthio)-IBMX	992:21	Koh	Redirect
Forumula 1	Formula I	993:1	Koh	Redirect
Pharma 4	Pharmacophore	998:2	Koh	Redirect
bioisos here	bioisostere	1000:1-2	Koh	Redirect
bioisis	bioisostere	1000:4	Koh	Redirect
bioisis, something	Bioisostere, is something	1000:5	Koh	Redirect
not the concept of	not the same concept as a	1000:11	Koh	Redirect
Bioisis theorism	bioisosterism	1001:1	Koh	Redirect
bioisis stere	bioisostere	1001:7	Koh	Redirect
place	proposed	1003:24	Koh	Redirect
where	when	1003:25	Koh	Redirect
Imposed	improve the	1004:4	Koh	Redirect
France	(France)	1005:11	ICOS Resp. to 3rd Set of ROGs	
ChemBase	"ChemBase"	1005:12	ICOS Resp. to 3rd Set of ROGs	
license or	licensor	1005:16	ICOS Resp. to 3rd Set of ROGs	
Les Ulis France	Les Ulis, France	1005:21	ICOS Resp. to 3rd Set of ROGs	
scientists	Scientists	1006:14	ICOS Resp. to 3rd Set of ROGs	
it is	as	1006:17	ICOS Resp. to 3rd Set of ROGs	
interrogatory.	interrogatory under Fed. R. Civ. P. 33 (d).	1007:3	ICOS Resp. to 3rd Set of ROGs	
had access	accessed	1007:22	ICOS Resp. to 3rd Set of ROGs	
Grodin	Grondin	1008:8	ICOS Resp. to 3rd Set of ROGs	
amididazole	imidazole	1019:17	Padwa	Direct
have	are	1020:7	Padwa	Direct
incredibly important	incredible importance	1020:19	Padwa	Direct
cash kneel	carbonyl	1021:10	Padwa	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 41 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 14, 2008 (D.I. 145)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
These have really a method fused onto an amidazole ring. That's very different from purine, because these extra oxygens in the carbonyl group have going to have a major impact	These have really a methyl fused onto an imidazole ring. That's very different from purine, because these extra oxygens in the carbonyl group are going to have a major impact	1021:12-14	Padwa	Direct
I'm important taps	importance	1023:4	Padwa	Direct
signability	solubility	1023:9	Padwa	Direct
tetrahydrofurins	tetrahydrofurans	1026:5	Padwa	Direct
tetrahydrofurin	tetrahydrofuran	1026:16	Padwa	Direct
indol	indole	1034:3	Padwa	Direct
Rommel	Flowers	1034:5	Padwa	Direct
indols	indoles	1034:15	Padwa	Direct
8,4-hydroxyphenylthio IBMX	8-(4-hydroxy-phenylthio)-IBMX	1035:8	Padwa	Direct
8-4 hydroxy phenylthio know IBMX	8-(4-hydroxy-phenylthio)-IBMX	1037:19-20	Padwa	Direct
8-4 hydroxy phenylthio IBMX	8-(4-hydroxy-phenylthio)-IBMX	1038:16	Padwa	Direct
65	6-5	1040:8	Padwa	Direct
of. five-ring	of five-ring	1040:19-20	Padwa	Direct
ruts	results	1040:24	Padwa	Direct
syn they sigh	synthesize	1042:15	Padwa	Direct
30,004DX	30040X	1068:17	Padwa	Cross
30,004DX	30040X	1068:20	Padwa	Redirect
GR 35723	GR 35273	1069:1	Padwa	Redirect
BBC E	BCCE	1069:8	Padwa	Redirect
12799	142799	1070:8	Padwa	Redirect
tetrahyrdo-beta-carboline	tetrahydro-beta-carboline	1070:12	Padwa	Redirect
Analogue 3 in X41. They're Example 1	Analogue 3 and Example 41.	1073:13	Padwa	Redirect
rows	rods	1077:16	Cote	Direct
cyclonucleotide	cyclic nucleotide	1081:17	Cote	Direct
guanyline	guanylate	1083:9	Cote	Direct
guanyline	guanylate	1083:14	Cote	Direct
phospholiation	phosphorylation	1083:17	Cote	Direct
says	say	1084:21	Cote	Direct
act	active	1084:24	Cote	Direct
con chewed	conclude	1090:14	Cote	Direct
PDE .16	PDE 6 was .16	1094:21	Cote	Direct
is	in	1104:24	Cote	Direct
Kokovetz	Kukovetz	1114:25	Cote	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 42 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 14, 2008 (D.I. 145)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
Kokovetz	Kukovetz	1116:24	Cote	Direct
Murzazadeh	Mirzazadeh	1117:21	Cote	Direct
Mann-Baker	May & Baker	1124:17	Cote	Direct
Exhibit HL	Exhibit LH	1125:2	Cote	Direct
cyclim GM	cyclic GMP	1134:11	Cote	Direct
phosphodiestera se	phosphodiesterase	1134:12	Cote	Direct
phosphodiestera se	phosphodiesterase	1134:18	Cote	Direct
sites	cites	1150:19	Cote	Cross
penal	penile	1152:7	Cote	Cross
guanyline	guanylyl	1152:9	Cote	Cross
penal	penile	1153:4	Cote	Cross

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 43 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 15, 2008 (D.I. 146)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

Now Reads	Should Read	Page: Line Nos	Witness	Examination Type
chemist tree	chemistry	1172:14	Rafferty	Direct
Formula 1	Formula I	1172:20	Rafferty	Direct
now	know	1173:25	Rafferty	Direct
structure	structural	1174:14	Rafferty	Direct
8-4 hydroxy phenylthio IBMX	8-(4-hydroxy-phenylthio)-IBMX	1174:23-24	Rafferty	Direct
and	an	1174:25	Rafferty	Direct
8-4 hydroxy phenylthio IBMX	8-(4-hydroxy-phenylthio)-IBMX	1177:7	Rafferty	Direct
wasn't have	wouldn't have	1180:2	Rafferty	Direct
IP 17.2	ID 17.2	1180:8	Rafferty	Direct
night row generals	nitrogens	1180:22	Rafferty	Direct
one, the	one, of the	1181:15	Rafferty	Direct
eight try neuro methyl IBMX	8-tri-fluoromethyl-IBMX	1182:11	Rafferty	Direct
eight bromo IBMX	8-bromo-IBMX	1182:11	Rafferty	Direct
phenylthio know IBMX	phenylthio IBMX	1182:13	Rafferty	Direct
week	weak	1184:4	Rafferty	Direct
an incorporated	a proper	1185:14	Rafferty	Direct
come pounds	compounds	1186:17	Rafferty	Direct
ethoxy	methoxy	1186:22	Rafferty	Direct
phenytio-	phenylthio-	1187:13	Rafferty	Direct
replace	replaced	1188:8	Rafferty	Direct
84 hydroxy phenyltio-IBMX	8-(4-hydroxy-phenylthio)-IBMX	1190:9	Rafferty	Direct
IB 17.4	ID 17.4	1190:16	Rafferty	Direct
represented formula 1	represented by Formula 1	1191:9-10	Rafferty	Direct
compound	compounds	1191:22	Rafferty	Direct
Dr. Simply regarded	Dr. Koh simply disregarded	1191:24	Rafferty	Direct
errors there were	reports for the	1192:20	Rafferty	Direct
compound	compounds	1193:15	Rafferty	Direct
compound	compounds	1193:19	Rafferty	Direct
figures	figure is	1194:18	Rafferty	Direct
BCEE	BCCE	1195:15	Rafferty	Direct
GR 35274	GR 35273	1196:9	Rafferty	Direct
GR 53273	GR 35273	1197:14	Rafferty	Direct
GR 53273X,	GR 35273X,	1197:16	Rafferty	Direct
GR 53273	GR 35273	1197:19	Rafferty	Direct
4231992	4/23/1992	1198:19	Rafferty	Direct
needs	leads	1200:12	Rafferty	Direct
are	were	1200:17	Rafferty	Direct

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 44 of 45

ERRATA SHEET
for Transcript of Bench Trial held on January 15, 2008 (D.I. 146)
Vanderbilt University v. ICOS Corporation
C.A. No. 05-506-SLR

8-4 hydroxy phenylthio IBMX	8-(4-hydroxy-phenylthio)-IBMX	1200:24-25	Rafferty	Direct
which	when	1201:21	Rafferty	Direct
two	to	1202:6	Rafferty	Direct
I.D.	ID	1202:19	Rafferty	Direct
been reasonable	been a reasonable	1205:3	Rafferty	Direct
nay	in a way	1205:4	Rafferty	Direct
structural	structure	1205:8	Rafferty	Direct
has	had	1205:12	Rafferty	Direct
I.D.	ID	1207:11	Rafferty	Direct
1982	1992	1207:23	Rafferty	Direct
nucleus	nitrogen	1209:24	Rafferty	Direct
AH 20950	AH 20905	1211:4	Rafferty	Direct
added	identified	1213:1	Rafferty	Direct
between	[delete between]	1215:1	Rafferty	Direct
come point	compounds	1215:25	Rafferty	Direct
was	were	1215:25	Rafferty	Direct
best	[delete best]	1218:1	Rafferty	Direct
exhibit	Figure	1218:5	Rafferty	Direct
PIP	opinion	1218:15	Rafferty	Direct
entirely --	entirely mine --	1226:11	Rafferty	Cross
Hench	Hansch	1229:4	Rafferty	Cross
con tapes	contains	1245:19	Rafferty	Cross
under	understand	1247:23	Rafferty	Cross
GR352273X	GR35273X	1248:19	Rafferty	Cross
1993	1992	1259:13	Rafferty	Cross
demonstrable	the month	1269:12	Rafferty	Cross
adduced	reduced	1275:8	Rafferty	Cross
Exhibit	objection	1305:3	Rafferty	Cross
Exhibit	objection	1305:10	Rafferty	Cross
Exhibit	objection	1305:17	Rafferty	Cross
GR 35723	GR 35273	1293:17	Rafferty	Redirect
GR 35723	GR 35273	1293:20	Rafferty	Redirect
35723	35273	1294:8	Rafferty	Redirect
inappropriate. liberties	inappropriate liberties	1297:17-18	Rafferty	Redirect
32573	35273	1297:24	Rafferty	Redirect
65	6-5	1302:14	Rafferty	Redirect

Case 1:05-cv-00506-SLR Document 148-2 Filed 02/22/2008 Page 45 of 45